Get access

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

Authors

  • Shuichi Kaneko,

    Corresponding author
    1. Novel Anticancer Agent Guideline Drafting Committee
    2. Study Group on New Liver Cancer Therapies
    3. Departments of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa
      Dr Shuichi Kaneko, 13-1 Kanazawa, Ishikawa, Japan 920-8641. Email: skaneko@m-kanazawa.jp
    Search for more papers by this author
  • Junji Furuse,

    1. Novel Anticancer Agent Guideline Drafting Committee
    2. Study Group on New Liver Cancer Therapies
    3. Medical Oncology, Kyorin University School of Medicine, Mitaka
    Search for more papers by this author
  • Masatoshi Kudo,

    1. Novel Anticancer Agent Guideline Drafting Committee
    2. Study Group on New Liver Cancer Therapies
    3. Gastroenterology, Kinki University, Higashiosaka
    Search for more papers by this author
  • Kenji Ikeda,

    1. Novel Anticancer Agent Guideline Drafting Committee
    2. Study Group on New Liver Cancer Therapies
    3. Hepatology, Toranomon Hospital, Tokyo
    Search for more papers by this author
  • Masao Honda,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology, Kinki University, Higashiosaka
    Search for more papers by this author
  • Yasunari Nakamoto,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology, Graduate School of Medicine, Fukui University, Fukui
    Search for more papers by this author
  • Morikazu Onchi,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Matsuyama
    Search for more papers by this author
  • Goshi Shiota,

    1. Study Group on New Liver Cancer Therapies
    2. Division of Molecular and Genetic Medicine, Tottori University Graduate School of Medicine, Tottori
    Search for more papers by this author
  • Osamu Yokosuka,

    1. Study Group on New Liver Cancer Therapies
    2. Departments of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    Search for more papers by this author
  • Isao Sakaida,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi
    Search for more papers by this author
  • Tetsuo Takehara,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka
    Search for more papers by this author
  • Yoshiyuki Ueno,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology, Tohoku University Graduate School of Medicine, Sendai
    Search for more papers by this author
  • Kazumasa Hiroishi,

    1. Study Group on New Liver Cancer Therapies
    2. Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, Tokyo
    Search for more papers by this author
  • Shuhei Nishiguchi,

    1. Study Group on New Liver Cancer Therapies
    2. Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Kakogawa
    Search for more papers by this author
  • Hisataka Moriwaki,

    1. Study Group on New Liver Cancer Therapies
    2. Departments of Gastroenterology, Gifu University Graduate School of Medicine, Gifu
    Search for more papers by this author
  • Kazuhide Yamamoto,

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Okayama
    Search for more papers by this author
  • Michio Sata,

    1. Study Group on New Liver Cancer Therapies
    2. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume
    Search for more papers by this author
  • Shuntaro Obi,

    1. Study Group on New Liver Cancer Therapies
    2. Departments of Hepatology, Kyoundo Hospital, Tokyo
    Search for more papers by this author
  • Shiro Miyayama,

    1. Study Group on New Liver Cancer Therapies
    2. Diagnostic Radiology, Fukuiken Saiseikai Hospital, Fukui
    Search for more papers by this author
  • Yukinori Imai

    1. Study Group on New Liver Cancer Therapies
    2. Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    Search for more papers by this author

  • This article was previously published in Japanese in Kanzo 52: 8, pp. 532–551. June 2011.

Dr Shuichi Kaneko, 13-1 Kanazawa, Ishikawa, Japan 920-8641. Email: skaneko@m-kanazawa.jp

Abstract

The “Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma” was prepared by the Study Group on New Liver Cancer Therapies established by the “Research Project on Emergency Measures to Overcome Hepatitis” under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents “clinical questions” on issues pertaining to medical care, makes “recommendations” on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of “scientific statements”.

Get access to the full text of this article

Ancillary